# GeoVax to Present at the Emerging Growth Conference on August 21, 2024
Canonical URL: https://biopharmsignal.com/news/GOVX/geovax-to-present-at-the-emerging-growth-conference-on-august-21-2024-dcf60383
Ticker: GOVX
Company: GeoVax Labs
Source: GeoVax Labs
Published: 2024-08-15 13:00 EST
## Summary

Company to Discuss Recent Mpox Developments as Well as Milestones Related to theBARDA Project NextGen Award for Its Next-generation COVID-19 Vaccine ...

## Article Body
Company to Discuss Recent Mpox Developments as Well as Milestones Related to the BARDA Project NextGen Award for Its Next-generation COVID-19 Vaccine

ATLANTA, GA, Aug. 15, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, is pleased to announce that it has been invited to present at the next Emerging Growth Conference being held August 21-22, 2024. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company’s Chairman and CEO, David Dodd, in real time.

Mr. Dodd will be presenting at 4:10pm ET on Wednesday, August 21, 2024. Following his presentation, Mr. Dodd will open the floor for questions, time permitting. Please submit your questions in advance to Questions@EmergingGrowth.com or ask your questions during the event and Mr. Dodd will do his best to get through as many of them as possible. Please register here to ensure you are able to attend the conference and receive any updates that are released. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference .

About the Emerging Growth Conference

The Emerging Growth Conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community. The conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of individual and institutional investors, as well as investment advisors and analysts. All sessions are conducted through video webcasts and take place in the Eastern time zone.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines for many of the world’s most threatening infectious diseases and therapies for solid tumor cancers. The company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine for which GeoVax was recently awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial to evaluate the efficacy of GEO-CM04S1 versus an approved COVID-19 vaccine. In addition, GEO-CM04S1 is currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. The Company has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com .

| Company Contact: |  | Investor Relations Contact: |  | Media Contact: |
| --- | --- | --- | --- | --- |
| info@geovax.com |  | austin.murtagh@precisionaq.com |  | sr@roberts-communications.com |
| 678-384-7220 |  | 212-698-8696 |  | 202-779-0929 |
## Recent Company News
- 2024-12-09 14:00 EST — [GeoVax Receives Notice of Allowance For Cancer Vaccine Patent](https://biopharmsignal.com/news/GOVX/geovax-receives-notice-of-allowance-for-cancer-vaccine-patent-64188cc4) — Source: GeoVax Labs
- 2024-11-26 14:00 EST — [GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference](https://biopharmsignal.com/news/GOVX/geovax-to-present-at-the-noble-capital-markets-twentieth-annual-emerging-growth--80440681) — Source: GeoVax Labs
- 2024-11-19 14:00 EST — [GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia](https://biopharmsignal.com/news/GOVX/geovax-announces-positive-interim-data-review-for-phase-2-clinical-trial-of-covi-efe6dd0a) — Source: GeoVax Labs
- 2024-11-12 21:00 EST — [GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update](https://biopharmsignal.com/news/GOVX/geovax-reports-third-quarter-2024-financial-results-and-provides-business-update-44c641df) — Source: GeoVax Labs
- 2024-11-05 14:00 EST — [GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024](https://biopharmsignal.com/news/GOVX/geovax-to-report-third-quarter-2024-financial-results-and-provide-corporate-upda-37cc2e92) — Source: GeoVax Labs
## Related News
- 2026-07-29 20:05 EST — SERA — [SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026](https://biopharmsignal.com/news/SERA/sera-prognostics-announces-conference-call-and-webcast-of-second-quarter-fiscal--2a2c0c5a)
- 2026-07-29 20:05 EST — VKTX — [Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/VKTX/viking-therapeutics-reports-second-quarter-2026-financial-results-and-provides-c-2f09b8ce)
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)